245 related articles for article (PubMed ID: 33402590)
41. Multiplex fluorescence in situ hybridization testing for anaplastic lymphoma kinase and c-ros oncogene 1 gene rearrangements on cytology smears in lung adenocarcinomas: comparative study with formalin-fixed paraffin-embedded sections.
Nambirajan A; Rana D; Samant K; Prabakaran A; Malik P; Jain D
J Am Soc Cytopathol; 2022; 11(3):154-164. PubMed ID: 35148960
[TBL] [Abstract][Full Text] [Related]
42. Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma.
Tang Z; Zhang J; Lu X; Wang W; Chen H; Robinson MK; Cheng J; Tang G; Medeiros LJ
Mod Pathol; 2018 Feb; 31(2):307-312. PubMed ID: 28914263
[TBL] [Abstract][Full Text] [Related]
43. ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization.
Williams AS; Greer W; Bethune D; Craddock KJ; Flowerdew G; Xu Z
Virchows Arch; 2016 Nov; 469(5):533-540. PubMed ID: 27562706
[TBL] [Abstract][Full Text] [Related]
44. Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study.
Bironzo P; Melocchi L; Monica V; Trebeschi D; Barbieri F; Maiello E; Migliorino MR; Lombardi A; Tiseo M; Righi L; Graziano P; Rossi G; Novello S
Pathologica; 2022 Aug; 114(4):278-287. PubMed ID: 36083243
[TBL] [Abstract][Full Text] [Related]
45. Concordance of Immunohistochemistry and Fluorescence In Situ Hybridization in the Detection of Anaplastic Lymphoma Kinase (ALK) and Ros Proto-oncogene 1 (ROS1) Gene Rearrangements in Non-Small Cell Lung Carcinoma: A 4.5-Year Experience Highlighting Challenges and Pitfalls.
Nambirajan A; Sood R; Khatoon W; Malik PS; Mohan A; Jain D
Arch Pathol Lab Med; 2023 Dec; ():. PubMed ID: 38054562
[TBL] [Abstract][Full Text] [Related]
46. A comparison of ALK gene rearrangement and ALK protein expression in primary lung carcinoma and matched metastasis.
Trejo Bittar HE; Luvison A; Miller C; Dacic S
Histopathology; 2017 Aug; 71(2):269-277. PubMed ID: 28316074
[TBL] [Abstract][Full Text] [Related]
47. Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer.
Cheung CC; Smith AC; Albadine R; Bigras G; Bojarski A; Couture C; Cutz JC; Huang WY; Ionescu D; Itani D; Izevbaye I; Karsan A; Kelly MM; Knoll J; Kwan K; Nasr MR; Qing G; Rashid-Kolvear F; Sekhon HS; Spatz A; Stockley T; Tran-Thanh D; Tucker T; Waghray R; Wang H; Xu Z; Yatabe Y; Torlakovic EE; Tsao MS
Lung Cancer; 2021 Oct; 160():127-135. PubMed ID: 34509095
[TBL] [Abstract][Full Text] [Related]
48. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended.
Savic S; Diebold J; Zimmermann AK; Jochum W; Baschiera B; Grieshaber S; Tornillo L; Bisig B; Kerr K; Bubendorf L
Lung Cancer; 2015 Aug; 89(2):104-9. PubMed ID: 26056079
[TBL] [Abstract][Full Text] [Related]
49. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
[TBL] [Abstract][Full Text] [Related]
50. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
[TBL] [Abstract][Full Text] [Related]
51. Retrospective study of ALK rearrangement and clinicopathological implications in completely resected non- small cell lung cancer patients in Northern Thailand: role of screening with D5F3 antibodies.
Tantraworasin A; Lertprasertsuke N; Kongkarnka S; Euathrongchit J; Wannasopha Y; Saeteng S
Asian Pac J Cancer Prev; 2014; 15(7):3057-63. PubMed ID: 24815447
[TBL] [Abstract][Full Text] [Related]
52. Identification of ROS1 rearrangement in gastric adenocarcinoma.
Lee J; Lee SE; Kang SY; Do IG; Lee S; Ha SY; Cho J; Kang WK; Jang J; Ou SH; Kim KM
Cancer; 2013 May; 119(9):1627-35. PubMed ID: 23400546
[TBL] [Abstract][Full Text] [Related]
53. Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers.
Park E; Choi YL; Ahn MJ; Han J
Pathol Res Pract; 2019 Jul; 215(7):152441. PubMed ID: 31085007
[TBL] [Abstract][Full Text] [Related]
54. Direct identification of ALK and ROS1 fusions in non-small cell lung cancer from hematoxylin and eosin-stained slides using deep learning algorithms.
Mayer C; Ofek E; Fridrich DE; Molchanov Y; Yacobi R; Gazy I; Hayun I; Zalach J; Paz-Yaacov N; Barshack I
Mod Pathol; 2022 Dec; 35(12):1882-1887. PubMed ID: 36057739
[TBL] [Abstract][Full Text] [Related]
55. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
56. ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer.
Boyle TA; Masago K; Ellison KE; Yatabe Y; Hirsch FR
Clin Lung Cancer; 2015 Mar; 16(2):106-11. PubMed ID: 25467930
[TBL] [Abstract][Full Text] [Related]
57. PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1.
Lee J; Park CK; Yoon HK; Sa YJ; Woo IS; Kim HR; Kim SY; Kim TJ
Thorac Cancer; 2019 Jan; 10(1):103-110. PubMed ID: 30475455
[TBL] [Abstract][Full Text] [Related]
58. Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer.
Mattsson JS; Brunnström H; Jabs V; Edlund K; Jirström K; Mindus S; la Fleur L; Pontén F; Karlsson MG; Karlsson C; Koyi H; Brandén E; Botling J; Helenius G; Micke P; Svensson MA
BMC Cancer; 2016 Aug; 16():603. PubMed ID: 27495736
[TBL] [Abstract][Full Text] [Related]
59. Detection of ALK rearrangements in 4002 Russian patients: The utility of different diagnostic approaches.
Demidova I; Grinevich V; Avdalian A; Imyanitov E; Gikalo M; Savelov N; Novikova I; Samuilenkova O; Tiurin V; Ulianova E; Tsimafeyeu I; Tjulandin S
Lung Cancer; 2017 Jan; 103():17-23. PubMed ID: 28024691
[TBL] [Abstract][Full Text] [Related]
60. ROS1 rearrangements define a unique molecular class of lung cancers.
Bergethon K; Shaw AT; Ou SH; Katayama R; Lovly CM; McDonald NT; Massion PP; Siwak-Tapp C; Gonzalez A; Fang R; Mark EJ; Batten JM; Chen H; Wilner KD; Kwak EL; Clark JW; Carbone DP; Ji H; Engelman JA; Mino-Kenudson M; Pao W; Iafrate AJ
J Clin Oncol; 2012 Mar; 30(8):863-70. PubMed ID: 22215748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]